Wiesfeld A C, Remme W J, Look M P, Kruijssen D A, van Hoogenhuyze D C
Cardiovascular Research Foundation, Sticares and Zuiderziekenhuis, Rotterdam, The Netherlands.
Am J Cardiol. 1992 Oct 15;70(11):997-1003. doi: 10.1016/0002-9149(92)90350-8.
The anti-ischemic efficacy of diltiazem may improve with increments in dosage and with additional beta-blocking therapy. However, the combined administration could lead to adverse effects through amplification of negative inotropic and chronotropic properties. To evaluate hemodynamic tolerability and safety of high-dose intravenous diltiazem in patients with coronary artery disease receiving long-term metoprolol treatment, 9 such patients were studied for 30 minutes after onset of intravenous diltiazem administration (0.5 mg/kg for 5 minutes, followed by 15 mg/hour). Diltiazem plasma levels peaked at 5 minutes (641 +/- 74 micrograms/liter), decreasing to 177 micrograms/liter at 30 minutes. Average metoprolol levels (43 +/- 12 micrograms/liter) did not change. Diltiazem immediately decreased systemic vascular resistance, left ventricular systolic and mean aortic pressures (29, 21 and 20%, respectively, at 5 minutes), and they remained significantly reduced at 30 minutes. Heart rate initially increased by 11% during the bolus infusion (p < 0.05). Concomitantly, contractility indexes Vmax and Vce40, measured at fixed heart rates, also increased significantly by 11%. Both heart rate and contractility indexes returned to baseline levels thereafter. Cardiac output increased by 10% (p = not significant), stroke index remained unchanged, but stroke work decreased significantly by 20%. Also, the tension-time index was significantly reduced (23%). Diltiazem induced moderate negative lusitropic effects, the first derivative of negative left ventricular pressure decline decreased by 12% and Tau 2 lengthened by 13%. Concomitantly, left ventricular filling pressure increased from 19 +/- 2 to 23 +/- 3 mm Hg, but only at 5 and 15 minutes. PQ, QRS and QTc intervals were not affected.(ABSTRACT TRUNCATED AT 250 WORDS)
地尔硫䓬的抗缺血疗效可能会随着剂量增加和联合β受体阻滞剂治疗而提高。然而,联合用药可能会因负性肌力和变时性作用的增强而导致不良反应。为评估长期接受美托洛尔治疗的冠心病患者静脉注射高剂量地尔硫䓬时的血流动力学耐受性和安全性,对9例此类患者在静脉注射地尔硫䓬(0.5mg/kg,持续5分钟,随后以15mg/小时的速度给药)开始后30分钟进行了研究。地尔硫䓬血浆水平在5分钟时达到峰值(641±74μg/升),30分钟时降至177μg/升。美托洛尔平均水平(43±12μg/升)未发生变化。地尔硫䓬立即降低了体循环血管阻力、左心室收缩压和平均主动脉压(5分钟时分别降低29%、21%和20%),30分钟时仍显著降低。在推注期间心率最初增加了11%(p<0.05)。同时,在固定心率下测量的收缩性指标Vmax和Vce40也显著增加了11%。此后心率和收缩性指标均恢复至基线水平。心输出量增加了10%(p无统计学意义),每搏指数保持不变,但每搏功显著降低了20%。此外,张力-时间指数显著降低(23%)。地尔硫䓬引起中度负性松弛作用,左心室压力下降的一阶导数降低了12%,Tau 2延长了13%。同时,左心室充盈压从19±2mmHg升高至23±3mmHg,但仅在5分钟和15分钟时出现。PQ、QRS和QTc间期未受影响。(摘要截短至250字)